Patent 7737283 was granted and assigned to Deciphera Pharmaceuticals on June, 2010 by the United States Patent and Trademark Office.
Novel compounds and methods of using those compounds for the treatment of inflammatory conditions are provided. In a preferred embodiment, modulation of the activation state of p38 kinase protein comprises the step of contacting the kinase protein with the novel compounds.